By Adriano Marchese

Canopy Growth's loss narrowed in its fiscal second quarter thanks to strong performance in both medical- and recreational-cannabis sales in Canada.

For the three months ended Sept. 30, the Smiths Falls, Ontario, cannabis company on Friday posted a significantly narrowed net loss of 1.64 million Canadian dollars ($1.12 million), or C$0.01 a share, compared with a loss of C$128.3 million, or C$1.48 a share, in the comparable quarter a year earlier.

According to FactSet, analysts were expecting a loss of C$0.16 a share.

Consolidated net revenue rose 6% to C$66.7 million, but fell short of analyst expectations for a greater rise to C$71.2 million.

Canopy said it saw a 30% rise in Canadian adult-use cannabis revenue, to C$24 million, thanks largely to growth in infused preroll joints and new all-in-one vapes. Canadian medical cannabis also got a boost, with revenue rising 17% to C$22 million as it benefited mainly from more insured patients and larger order sizes.

On the international front, Canopy faced supply-chain issues in Europe that dragged revenue down 39% to C$5 million.

Meanwhile, vaporizer brand Storz & Bickel's net revenue fell 10% in the quarter. The brand was up against strong year-earlier figures, as well as continued economic uncertainty in its key markets.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

November 07, 2025 07:56 ET (12:56 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.